Stopping Cancer Early – The Best Possible Investment


Canary Scientists are on the right track!

October 14, 2021

Canary Center continues as a world class facility, acting as a hub for innovative research, collaborations, cross-disciplined studies, and international partnerships.

After their train ride, our scientists gave an informative update at a recent meeting observing distancing measures. Subjects covered included the Canary Center at Stanford, Ovarian and Prostate Programs and examples of work from the lab of Dr. Joseph DeSimone, who has been appointed as the inaugural Sanjiv Sam Gambhir Professor in Translational Medicine.

Below are two highlights and a link to a 2-page report.

Canary Ovarian Initiative is focusing on the microenvironment of the fallopian tubes, high grade serous carcinoma originates in the fallopian tubes, to look for changes that signal cancer.

  • Using bioinformatics and methylated DNA to determine origins of ovarian cancer.
  • Looking for changes in the fallopian tubes decades before cancer can be diagnosed, especially for high risk women (i.e. BRCA mutations). Single cell sequencing – looking for changes in cells that can signal cancer early.
  • Remaining patient-focused for compassion and team-focused for efficiency.

Prostate Cancer Team and the Prostate Active Surveillance Study (PASS), more than a decade on, helps patients in the study as well as informing the medical profession on ways to understand which men are at greatest risk, requiring aggressive treatment versus those who have slow growing cancer. Recent Pass accomplishments include:

  • Advanced imaging with MRI.
  • African Americans do not have worse outcomes in active surveillance
  • Created models to predict non-progression.
  • Fewer painful prostate biopsies.
  • PASS Risk calculator to aid patients and physicians with decisions.
  • High risk patients (BRCA mutation) personalized screening.

Read the full update report here:

Canary Brief Report Oct 2021